<DOC>
	<DOCNO>NCT00146809</DOCNO>
	<brief_summary>Study Hypothesis : - Does treatment Minocycline 2 x daily 2 x 50 mg effect progression clinical symptom diagnosis patient MSA ? Background Rationale : - The Parkinson-Syndrome characterise clinical triad akinesis , rigor passive tremor , cause Parkinson ’ disease ( PD ) 70 % case ( Oertel et al. , 2003 ) . However , beside Parkinson ’ disease several , extent rare , so-called atypical Parkinson ’ syndrome . The two frequent atypical Parkinson-Syndromes - Multi-System-Atrophy ( MSA ) Progressive Supranuclear Palsy ( PSP ) . Due often much varying course since well know , diseases frequently diagnose late diagnose . Nevertheless , early diagnosis substantial treatment , since prognosis therapy atypical Parkinson Syndromes differ essentially PD . Whereas neuronal death cell PD restrict essentially Substantia nigra , dominant destruction neuron brain stem , Cerebellum Striatum additionally happen case MSA PSP . - Up adequate treatment strategy disposal . Initially give L-Dopa lead improvement &lt; 10 % patient . - Minocycline antibiotic belonging group Tetracyclines . - Recently , could demonstrate Minocycline neuroprotective impact besides anti-inflammatory impact .</brief_summary>
	<brief_title>Study About Efficacy Safety Treat Multi-System-Atrophy</brief_title>
	<detailed_description>Study Hypothesis : - Does treatment Minocycline 2 x daily 2 x 50 mg effect progression clinical symptom diagnosis patient MSA ? - Minocycline antibiotic belonging group Tetracyclines . It apply treat bacterial infection skin disorder ( acne ) , study prove good effect inflammatory change rheumatoid arthritis ( O´Dell , 1999 ; O´Dell et al. , 2001 ; Pillemar et . al. , 1997 ) . In four-years-lasting double-blind-placebo-controlled study could demonstrate Minocycline represent effective therapy seropositive rheumatoid arthritis . Moreover , long term therapy low side effect rate observe ( O´Dell et al. , 1999 ; Langevitz et al. , 2000 ; Alarcon , 2000 ) . - Recently , could demonstrate Minocycline neuroprotective impact besides anti-inflammatory impact . In focal global animal stroke model clearly reduce stroke volume treatment Minocycline comparison untreated group ( Yrjanheikki , 1998 ; Yrjanheikki , 1999 ) . These data replicate various group , group well ( unpublished data ) . Furthermore , neuroprotective impact Minocycline examine number animal experience ( Chen et al. , 2000 ; Zhu et al. , 2002 ; Kriz et al . 2002 , Sanchez et al. , 2001 ; Van Den Bosch et al. , 2002 ; Popovic et al. , 2002 ) : amyotrophic lateral sclerosis , M. Huntington , trauma , multiple sclerosis.In trial could demonstrate Minocycline slow neuronal cell death . - Recently , cooperation American colleague able demonstrate Minocycline posse high neuroprotective potency MPTP-Mouse model , ( animal-model Parkinson ’ disease , degeneration neuronal cell basal ganglia occurs ( Lin et al. , 2001 ; Du et al. , 2001 ) . Dependent applied dosage ( 30-120 mg/kg ) , neuroprotection 77 % could observe . In result could prove , NO well Caspase-1 play important role pathogenesis cell death . Both , expression iNOS activation Caspase-1 could block presence Minocycline animal-model cell culture trial . In addition , decrease inflammatory microglia activation examine brain section presence Minocycline . Similar result could present study group Przedborski ( Wu et al. , 2002 ) . - In various study could demonstrate regulation iNOS well activation Microglia MSA play important role . This activation Microglia person prove Positron-emission-tomography ( PET ) Benzodiazepine-Ligands PK11195 . PK11195 ( 1- ( 2-chlorophenyl ) –N-methyl-N- ( 1-methylpropyl ) -3isoquinoline- carboxamide ) highly specific Ligand peripheral Benzodiazepine-binding site ( PBBS ) ( Leong et al. , 1996 ) . As normal brain binding site PK11195 verify , significant increase PBBS-Expression activate microglia neuronal cell death verify ( Gerhard et al. , 2001 ) . - The result examination result literature suggest Minocycline could also effect neuro-degenerative disease particularly effect MSA . In USA study already examine impact orally give Minocycline patient Chorea Huntington amyotrophic lateral sclerosis take place . The National Institutes Health ( NIH ) USA perform multicentre , double-blind study effect Minocycline Parkinson ’ Disease ( NIH website , www.nih.gov ) . - In study , effectiveness Minocycline progression clinical symptom MSA shall examine .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>age ≥ 40 &lt; = 75 year Diagnosis MSAP accordance consensus criterion ( Gilman et al. , 1999 ; appendix ) UMSARS IV &lt; = 3 Patient must capable understanding informed consent Written consent participation study Diseases associate demential syndrome Dimming consciousness Any chronical inflammatory disease ( Crohn ’ disease , ulcerative colitis , C.a . hepatitis , C.a . pancreatitis ) Any malignant tumour disease Chronical alcohol addiction Severe Diabetes mellitus Type I II ( HbA1c &gt; 8 % ) AVBlock ≥ 2nd degree Atrial flutter , atrial fibrillation Tachycardia ( &gt; 100 bpm ) Bradycardia ( &lt; 60 bpm ) Highblood pressure ( systolic &gt; 180 mm Hg , diastolic : &gt; 110 mg HG ) Heart insufficiency ( NYHA &gt; 2 ) Pericarditis , pericardial effusion Heart attack within last six month inclusion study , ACVB , C.a . myocarditis Severe kidney insufficiency ( Creatinine &gt; 3 mg/dl ; Urea &gt; 150 mg/dl ) Hepatic insufficiency ( GOT &gt; 3 x ULN ; GPT &gt; 3 x ULN ) Ulcer disease Pneumonia , meningitis within 12 week inclusion study Any immunosuppressive cytotoxic therapy within last year inclusion study Any antibacterial antiviral therapy within last six week inclusion study Any systemic fungal infection within last year inclusion study Any positive family anamnesis autoimmune diseases Pregnancy nursing Severe psychiatric disease within last six month require hospitalisation , attempt suicide anamnesis , florid psychosis Seizure disorder Concomitant take follow drug : Riluzole , Carbamazepine , Phenytoine , Primidone , Colestyramine , activate charcoal , cumarin , Cyclosporine , Methotrexate , Methoxyflurane , Theophylline , Phenobarbital ; drug class : Antacids ( contain Al , Mg , Ca ) , Retinoids , Digitalis Glycosides Known hypersensitivity Minocycline Tetracyclines Simultaneous participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Multi-System-Atrophy</keyword>
	<keyword>Minocycline</keyword>
</DOC>